Brazikumab  (Synonyms: AMG 139; MEDI2070)

Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a K_D of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease^[1].

Human IgG2 lambda

Human IgG2 lambda, Isotype Control

Human

Brazikumab inhibits the binding of both recombinant and native IL-23 to its receptors stably expressed in COS cells with IC₅₀s of 188 and 284 pM, respectively^[1].
Brazikumab inhibits the production of IFN-γ in NK cells stimulated by human native or recombinant IL-23 (in association with IL-18) with IC₅₀s of 238 and 93 pM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

51561  [NCBI]

Q9NPF7

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.82 kDa

1610353-18-8

Liquid

Colorless to light yellow

[Brazikumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 lambda

• [1]. Currò D, et, al. Frontiers in Drug Research and Development for Inflammatory Bowel Disease. Front Pharmacol. 2017 Jun 23;8:400.  [Content Brief]

  [2]. Al-Bawardy B, et, al. Novel and Emerging Therapies for Inflammatory Bowel Disease. Front Pharmacol. 2021 Apr 14;12:651415.  [Content Brief]